NCT01958112View on ClinicalTrials.gov

GSK1120212+GSK2141795 for Cervical Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Cervical Cancer
Interventions
DRUG

GSK1120212 (trametinib)

Trametinib dose is 1.5 mg orally once per day

DRUG

GSK2141795

The dose of GSK2141795 is 50 mg orally once per day

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Dana-Farber Cancer Institute

OTHER